Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Outcome domains for studies of acute and chronic gout.

Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, Sivera F, Singh J, Evans R, Waltrip RW, Diaz-Torne C, MacDonald P, McQueen F, Perez-Ruiz F.

J Rheumatol. 2009 Oct;36(10):2342-5. doi: 10.3899/jrheum.090370.

PMID:
19820223
2.

Progress in measurement instruments for acute and chronic gout studies.

Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, Schlesinger N, Evans R, Edwards NL, Sivera F, Diaz-Torne C, MacDonald PA, McQueen FM, Schumacher HR.

J Rheumatol. 2009 Oct;36(10):2346-55. doi: 10.3899/jrheum.090371.

PMID:
19820224
3.

A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout.

Taylor WJ, Schumacher HR Jr, Baraf HS, Chapman P, Stamp L, Doherty M, McQueen F, Dalbeth N, Schlesinger N, Furst DE, Vazquez-Mellado J, Becker MA, Kavanaugh A, Louthrenoo W, Bardin T, Khanna D, Simon LS, Yamanaka H, Choi HK, Zeng X, Strand V, Grainger R, Clegg D, Singh JA, Diaz-Torne C, Boers M, Gow P, Barskova VG.

Ann Rheum Dis. 2008 Jun;67(6):888-91. Epub 2007 Nov 29. Erratum in: Ann Rheum Dis. 2008 Nov;67(11):1652.. Mellado, J Vazquez [corrected to Vazquez-Mellado, J].

PMID:
18055475
4.

Outcome evaluations in gout.

Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N, Khanna D, Furst DE, Becker MA, Dalbeth N, Edwards NL.

J Rheumatol. 2007 Jun;34(6):1381-5.

PMID:
17552064
5.

Quality of life and disability in patients with treatment-failure gout.

Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, Edwards L, Kawata AK, Frank L, Waltrip R, Maroli A, Huang B; Gout Natural History Study Group., Sundy JS.

J Rheumatol. 2009 May;36(5):1041-8. doi: 10.3899/jrheum.071229. Epub 2009 Mar 30.

PMID:
19332629
6.

Establishing outcome domains for evaluating treatment of acute and chronic gout.

Grainger R, Taylor WJ.

Curr Opin Rheumatol. 2008 Mar;20(2):173-8. doi: 10.1097/BOR.0b013e3282f36cf1. Review.

PMID:
18349747
7.

Outcome measures for acute and chronic gout.

Schumacher HR Jr, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, Joseph-Ridge N, Schlesinger N, Horowitz Z, Saag K, Boice JA, Yamanaka H; OMERACT 7 Special Interest Group..

J Rheumatol. 2005 Dec;32(12):2452-5. Review.

PMID:
16331785
8.

Toward a valid definition of gout flare: results of consensus exercises using Delphi methodology and cognitive mapping.

Taylor WJ, Shewchuk R, Saag KG, Schumacher HR Jr, Singh JA, Grainger R, Edwards NL, Bardin T, Waltrip RW, Simon LS, Burgos-Vargas R.

Arthritis Rheum. 2009 Apr 15;61(4):535-43. doi: 10.1002/art.24166.

9.

Concerns of patients with gout are incompletely captured by OMERACT-endorsed domains of measurement for chronic gout studies.

Diaz-Torne C, Pou MA, Castellvi I, Corominas H, Taylor WJ.

J Clin Rheumatol. 2014 Apr;20(3):138-40. doi: 10.1097/RHU.0000000000000090.

PMID:
24662554
10.

Quality of life and quality of care for patients with gout.

Singh JA.

Curr Rheumatol Rep. 2009 Apr;11(2):154-60. Review.

11.

Outcome measures in acute gout: a systematic literature review.

Dalbeth N, Zhong CS, Grainger R, Khanna D, Khanna PP, Singh JA, McQueen FM, Taylor WJ.

J Rheumatol. 2014 Mar;41(3):558-68. doi: 10.3899/jrheum.131244. Epub 2013 Dec 15. Review.

12.

OMERACT endorsement of measures of outcome for studies of acute gout.

Singh JA, Taylor WJ, Dalbeth N, Simon LS, Sundy J, Grainger R, Alten R, March L, Strand V, Wells G, Khanna D, McQueen F, Schlesinger N, Boonen A, Boers M, Saag KG, Schumacher HR, Edwards NL.

J Rheumatol. 2014 Mar;41(3):569-73. doi: 10.3899/jrheum.131246. Epub 2013 Dec 15.

13.

Gout and quality of life.

Kim SY, Choi HK.

J Rheumatol. 2009 May;36(5):865-8. doi: 10.3899/jrheum.090034. No abstract available.

PMID:
19435969
14.

Foot pain, impairment, and disability in patients with acute gout flares: A prospective observational study.

Rome K, Frecklington M, McNair P, Gow P, Dalbeth N.

Arthritis Care Res (Hoboken). 2012 Mar;64(3):384-8. doi: 10.1002/acr.20670.

15.

Updates in the management of gout.

Keith MP, Gilliland WR.

Am J Med. 2007 Mar;120(3):221-4. Review.

PMID:
17349440
16.

Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers.

Stamp LK, Zhu X, Dalbeth N, Jordan S, Edwards NL, Taylor W.

Semin Arthritis Rheum. 2011 Jun;40(6):483-500. doi: 10.1016/j.semarthrit.2010.09.003. Epub 2010 Nov 5. Review.

PMID:
21056459
17.

Do patient preferences for core outcome domains for chronic gout studies support the validity of composite response criteria?

Taylor WJ, Brown M, Aati O, Weatherall M, Dalbeth N.

Arthritis Care Res (Hoboken). 2013 Aug;65(8):1259-64. doi: 10.1002/acr.21955.

18.

Patient-reported outcomes in chronic gout: a report from OMERACT 10.

Singh JA, Taylor WJ, Simon LS, Khanna PP, Stamp LK, McQueen FM, Neogi T, Gaffo AL, Becker MA, MacDonald PA, Dabbous O, Strand V, Dalbeth ND, Aletaha D, Edwards NL, Schumacher HR Jr.

J Rheumatol. 2011 Jul;38(7):1452-7. doi: 10.3899/jrheum.110271.

19.

[Gout: current views. Stage oriented treatment].

Fedorova NE, Grigor'eva VD.

Klin Med (Mosk). 2002;80(2):9-13. Review. Russian.

PMID:
11898731
20.

Diagnosis of gout.

Schlesinger N.

Minerva Med. 2007 Dec;98(6):759-67. Review.

PMID:
18299687

Supplemental Content

Support Center